Outlook Therapeutics, Inc.OTLKNASDAQ
Loading
OTLK Revenue Growth (YoY Quarterly)•+0.00%
Stock Alarm Pro
Growth Metrics
Latest: Q4 2025vs Q3 2025
Revenue GrowthGross Profit GrowthEBITDA GrowthOperating Income GrowthNet Income GrowthEPS GrowthEPS Diluted GrowthWeighted Average Shares GrowthWeighted Average Shares Diluted GrowthDividends per Share Growth
+0.00%
+154.0pp
+0.00%
+1285.4pp
+0.00%
+354.4pp
+0.00%
+0.0pp
-232.69%
+100.9pp
-152.78%
+69.8pp
-152.78%
+115.0pp
+148.43%
+60.8pp
+5.13%
-32.2pp
+0.00%
+0.0pp
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +0.00% | +0.00% | +0.00% | -153.95% | +0.00% |
| Gross Profit Growth | +0.00% | +0.00% | +0.00% | -1285.37% | +0.00% |
| EBITDA Growth | +0.00% | +0.00% | -145.17% | -354.43% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | -145.38% | -333.58% | -232.69% |
| EPS Growth | +0.00% | +0.00% | -128.80% | -222.58% | -152.78% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | -267.74% | -152.78% |
| Weighted Average Shares Growth | +86.23% | +116.36% | +58.77% | +87.59% | +148.43% |
| Weighted Average Shares Diluted Growth | +86.23% | +116.36% | +45.07% | +37.34% | +5.13% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | -100.00% |
| Asset Growth | -21.58% | -67.68% | -52.45% | +64476476.71% | +7.25% |
| Book Value per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Debt Growth | -15.09% | -25.54% | +6.03% | +832839.08% | +18.90% |
| R&D Expense Growth | +113.29% | -67.38% | -36.31% | -52.26% | -62.38% |
| SG&A Expenses Growth | +106.20% | +47.02% | +15.77% | -0.26% | -27.91% |
1 / 4